A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy

Morten T. Veno1, Cristina R. Reschke1b,c, Gareth Morris1b,c,d,1, Niamh M. C. Connolly1b, Junyi Su1b, Yan Yan1a, Tobias Engel1b,c, Eva M. Jimenez-Mateos1b, Lea M. Harder1a, Dennis Pultz1a, Stefan J. Hausberger1b, Ajay Pal1b, Janosch P. Heller1b,c,d, Aoiife Campbell1b, Elena Langa1b, Gary P. Brennan1b,c, Karen Conboy1b, Amy Richardson1d, Braxton A. Norwood1h,1i, Sara S. Costard1h,i,1l, Valentin Neuberth1j, Federico Del Gallo1k, Beatrice Salvetti1h, Vamsidhar V. Rangovoor1b, Amaya Sanz-Rodrıguez1b,c, Juha Mulli1l, Paolo F. Fabene1b,c, R. Jeroen Pasterkamp1b, Jochen H. M. Prehn1b,c, Stephanie Schorge1d,1f, Jens S. Andersen1a, Felix Rosenow1h,i,1j, Sebastian Bauer1h,i,1l,1j, Jørgen Kjems1a,1l, and David C. Henshall1b,c,1,2

1Interdisciplinary Nanoscience Centre, Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark; 2Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, D02 YN77, Ireland; 3FutureNeuro, The Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, Dublin, D02 YN77, Ireland; 4Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom; 5Center for Experimental Bioinformatics, University of Southern Denmark, DK-5230 Odense M, Denmark; 6Department of Neuroscience, Expesinc Inc, Kalispell, MT 59901; 7Diagnostics Development, FYR Diagnostics, Missoula, MT 59801; 8Epilepsy Center, Department of Neurology, Philippus University Marburg, 35043, Marburg, Germany; 9Epilepsy Center Frankfurt Rhine-Main, Neurocenter, University Hospital Frankfurt and Center for Personalized Translational Epilepsy Research, Goethe University Frankfurt, 69128, Frankfurt, Germany; 10Oscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, 18051, Germany; 11Department of Neurosciences, Biomedical and Movement Sciences, University of Verona, 8 – 37134, Verona, Italy; 12Affiliated Partner of the European Reference Network Epicare, Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, 3584 CG, Utrecht, The Netherlands; 13Research and Development, BC Platforms, FI-02130, Espoo, Finland and 14UCL School of Pharmacy, University College London, London, London WC1X, United Kingdom

Edited by Hee-Sup Shin, Institute for Basic Science, Daejeon, South Korea, and approved May 22, 2020 (received for review November 12, 2019)

Temporal lobe epilepsy is the most common drug-resistant form of epilepsy in adults. The reorganization of neural networks and the gene expression landscape underlying pathophysiological network behavior in brain structures such as the hippocampus has been suggested to be controlled, in part, by microRNAs. To systematically assess their significance, we sequenced Argonaute-loaded microRNAs to define functionally engaged microRNAs in the hippocampus of three different animal models in two species and at six time points between the initial precipitating insult through to the establishment of chronic epilepsy. We then selected commonly up-regulated microRNAs for a functional in vivo therapeutic screen using oligonucleotide inhibitors. Argonaute sequencing generated a 1.44 billion small RNA reads of which up to 82% were microRNAs, with over 400 unique microRNAs detected per model. Approximately half of the detected microRNAs were dysregulated in each epilepsy model. We prioritized commonly up-regulated microRNAs that were fully conserved in humans and designed custom antisense oligonucleotides for these candidate targets. Antiseizure phenotypes were observed upon knockdown of mir-10a-5p, mir-21a-5p, and mir-142a-5p and electrophysiological analyses indicated broad safety of this approach. Combined inhibition of three of these microRNAs reduced spontaneous seizures in epileptic mice. Proteomic data, RNA sequencing, and pathway analysis on predicted and validated targets of these microRNAs implicated derepressed TGF-β signaling as a shared seizure-modifying mechanism. Correspondingly, inhibition of TGF-β signaling occluded the antiseizure effects of the antagonists. Together, these results identify shared, dysregulated, and functionally active microRNAs during the pathogenesis of epilepsy which represent therapeutic antiseizure targets.

antisense oligonucleotide | biomarker | epigenetic | epilepsy | noncoding RNA

Temporal lobe epilepsy (TLE) is characterized by seizures arising from or involving the hippocampus and is the most common focal epilepsy syndrome in adults (1). TLE is frequently refractory to pharmacotherapy, often necessitating surgical resection of involved brain structures (2). The most common pathological finding within the removed hippocampus is select neuron loss

Significance

Temporal lobe epilepsy is commonly drug resistant and is associated with dysregulated hippocampal gene expression. MicroRNAs are short noncoding RNAs which control protein levels by binding target mRNAs via Argonaute proteins. We sequenced Argonaute-bound microRNAs from the hippocampus of three rodent epilepsy models, identifying common and unique functioning microRNAs at each stage of epileptogenesis. We designed oligonucleotide inhibitors against six microRNAs shared among models in chronic epilepsy and show three of these protected against acute and spontaneous seizures in a mouse model. We demonstrate that normal brain physiology is not obviously disrupted by these treatments and used a multomics approach to identify a common mechanistic pathway for the therapeutic protective effects. Overall, these studies reveal potential treatments for drug-resistant epilepsy.

Author contributions: M.T.V., C.R.R., G.M., P.F.F., R.J.P., J.H.M.P., S.S., J.S.A., F.R., S.B., J.K., and D.C.H. designed research; M.T.V., C.R.R., G.M., N.M.C.C., J.S., Y.T., E.M.J.-M., L.M.H., D.P., S.J.H., A.P., J.P.H., A.C., E.L., G.P.B., K.C., A.R., B.A.N., L.S.C., V.N., F.D.G., B.S., V.R.V., A.S.-R., J.M., and S.B. performed research; M.T.V., C.R.R., G.M., N.M.C.C., J.S., Y.T., E.M.J.-M., L.M.H., D.P., J.P.H., A.C., E.L., B.A.N., L.S.C., V.N., F.D.G., B.S., V.R.V., A.S.-R., J.M., I.S.A., and S.B. analyzed data; and G.M. and D.C.H. wrote the paper.

Competing interest statement: D.C.H. reports US Patent No. US 9,803,200 B2 “Inhibition of microRNA-134 for the treatment of seizure-related disorders and neurologic injuries.” This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: The sequencing data reported in this paper have been deposited to the gene expression omnibus (GEO) under accession no. GSE137473. The proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD019098. Custom analysis codes are available in Github at https://github.com/g-morris/Ago2Seq. The Data deposition code has been deposited to the gene expression omnibus (GEO) under accession no. GSE137473. The proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD019098. Custom analysis codes are available in Github at https://github.com/g-morris/Ago2Seq.

1M.T.V., C.R.R., G.M., S.B., J.K., and D.C.H. contributed equally to this work.
2To whom correspondence may be addressed. Email: dhenshall@ircc.ie.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1919313117/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1919313117
and gliosis (3). Resected tissue from TLE patients also features 
neuroinflammation and remodeling of neuronal networks at both 
micro- and macroscopic scale (4, 5). Recent sequencing and array-
based profiling of protein-coding transcripts and systems biology 
approaches have generated deep insights into the molecular path-
ophysiology and helped identify novel classes of molecule for 
therapeutic targeting (6–9).

MicroRNAs (miRNAs) are critical for shaping the gene expression 
landscape in the brain (10). They are short noncoding 
RNAs that primarily function posttranscriptionally, conferring 
precision to cellular protein fluctuations (11, 12). Biogenesis of 
miRNAs involves nuclear processing of a primary transcript 
followed by terminal loop processing in the cytoplasm, resulting in 
a miRNA duplex from which one strand is selected by an 
Argonaute (Ago) protein (13). Argonaute-2 (Ago2) is critically 
important for miRNA function, enriched in the hippocampus and, 
uniquely among Ago proteins, can directly cleave target 
RNAs (14). After miRNA loading and the formation of a RNA-
induced silencing complex (RISC), potential miRNA targets are 
selected through imperfect base pairing between miRNA and 
miRNA (15). Upon identifying regions of sufficient comple-
mentarity, typically 7- to 8-mt matches between the miRNA and 
the 3′-untranslated region of the target mRNA, the RISC re-
ruits further proteins, leading to translational repression or 
mRNA decay (16). Individual miRNAs often have multiple 
targets, increasing the scope for influencing several pathways or 
enhanced regulation of single pathways by multiple miRNAs, 
which may be an advantage for the treatment of TLE (11, 12).

Spatiotemporal changes to miRNA expression have been reported 
in the hippocampus following epileptogenic brain injuries and these 
persist in established epilepsy (17, 18). In parallel, in vivo deployment of 
oligonucleotide miRNA inhibitors (antagomirs) has demonstrated 
functional roles for a few miRNAs in seizure control and epilepto-
genesis (19, 20). It remains unknown how many more miRNAs 
may be suitable targets in epilepsy. Recent efforts have identified 
miRNAs dysregulated in TLE (21–23) but no study to date has focused on quantifying the amounts of functional Ago2-loaded miRNAs that are shared between TLE models. This is important since the specific enrichment for Ago2-loaded miRNAs provides greater coverage of the miRNA landscape and better predicts the regulatory potential of miRNAs (24).

Here, we performed small RNA sequencing (RNA-seq) of 
Ago2-loaded miRNAs from three different animal models across 
all phases of epilepsy development in two rodent species. Based 
on this resource, we deployed an in vivo antagomir screen and 
identified several antiseizure and neuroprotective phenotypes 
from multiple miRNAs, which may be an advantage for the treatment of TLE (11, 12). We hypothesized that the up-regulated miRNAs shared in the chronic epilepsy phase across the three models would be enriched for regulators of brain excitability, and we selected those which were 
fully conserved in humans. To test this, we designed custom locked 
nucleic acid (LNA)-modified oligonucleotide miRNA inhibitors 
(antagomirs) and used these to assess seizure responses after in vivo 
knockdown of miRNAs (Figs. 4 A and B). We excluded miR-132-3p 
and miR-146a-5p to prioritize miRNAs not previously linked to 
epilepsy and excluded miR-21a-3p because it is not fully conserved 
in humans, therefore limiting translational potential. Instead, we 
selected the fully conserved miR-21a-5p, which also satisfied basal 
expression criteria and up-regulation (at least 15%) in all three 
models. Mice received an intracerebroventricular injection of one of 
six targeting antagomirs (Fig. 4 B), a scrambled antagomir (Scr) or 
vehicle (phosphate buffered saline [PBS]) 24 h before induction of 
status epilepticus (SE) by an intraamygdala microinjection of kainic 
acid (Fig. 4 D). This procedure ensures an optimal miRNA knock-
down at the time of testing seizure responses (29). EEG recordings 
were used to assess seizure severity and brains were later processed 
to quantify irreversible hippocampal damage (29).

Seizure severity, as determined by analysis of EEG total power (29), was significantly reduced during SE in mice preinjected with 
antagomirs against miR-10a-5p, miR-21a-5p, and miR-142a-5p (Fig. 4 C and D). Seizure burden, determined by measuring only 
ictal epileptiform activity (29), was significantly reduced by the 
same antagomirs and was also significant for anti-miR-431-5p (Fig. 4 E). 
Analysis of the brains from mice killed 24 h after SE revealed sig-
nificant neuroprotection for five of the six antagomirs (those tar-
getting miRNAs -10a-5p, -21a-5p, -27a-5p, -142a-5p, and -431-5p), 
relative to controls (Fig. 4 F and G). These results suggest that a 
high proportion of the shared miRNAs up-regulated in the chronic 
phase of experimental epilepsy may be maladaptive, contributing to 
enhanced network excitability and neuronal damage. Consequently, 
their targeting may offer approaches to control seizures.

Knockdown of miR-10a-5p, -21a-5p, and -142a-5p Has Limited Biophysical 
and Functional Effects in Naïve Rat Brains. Current antiseizure drugs are 
associated with side effects arising from nonspecific dampening of 
brain excitability (1, 2). Focusing on the miRNAs which showed
Fig. 1. Experimental design and small RNA sequencing. (A) Schematic showing the full study design. Step 1: Three rodent models of epilepsy were generated: IAKA (intraamygdala kainic acid-induced status epilepticus in C57BL/6 mice), PILO (pilocarpine-induced status epilepticus in NMRI mice), and PPS (perforant pathway stimulation-induced hippocampal lesioning in Sprague-Dawley rats). Step 2: Hippocampi were extracted at six (mice) or seven (rat) time points and processed for Ago2 immunoprecipitation and small RNA sequencing (Ago2-seq). Step 3: miRNAs with consistent up-regulation in all three models were selected for an antagomir-based screen for antiseizure phenotypes and neuroprotection. Step 4: Pathway modeling and biophysical analyses were used to investigate the function of the miRNAs. (B) The read mapping distribution for the three rodent models. Note, the majority of small RNA reads mapped to miRNAs. (C) Expression of the top 50 miRNAs between the three models showing highly similar expression levels.
Fig. 2. Extensive dysregulation of Ago2-loaded miRNAs across all phases of epilepsy development. (A) The 50 most significantly differentially expressed miRNAs are shown as a heatmap covering all samples from IAKA, PILO, and PPS models. Top annotation shows epileptic animals as black and control animals as gray. Shown are z scores of log2-transformed RPM values. (B) Examples of individual miRNA expression responses from the PPS model. Shown are miR-132 and miR-146 and potential novel epilepsy-associated miRNAs, miR-127, -24, -434, and -410. (C) Clustering analysis shows that miRNAs from the miR-17–92 cluster peak at the day of first spontaneous seizure (DOFS). miR-142-3p also peaks at DOFS, though not transcribed from the miR-17–92 cluster. Also shown are miR-32-5p and miR-190b-5p, both peaking at DOFS.
the most robust antiseizure phenotypes when targeted (miR-10a-5p, miR-21a-5p, and miR-142a-5p), we next assessed whether their knockdown had any adverse effects. We conducted a range of electrophysiological assessments, originally developed for antagomir-injected rats (30). We prepared ex vivo brain slices from the rats 2 to 4 d after antagomir injection, to coincide with maximal miRNA knockdown (29). Multiple electrophysiological measurements were unchanged in antagomir-injected animals, including population

Fig. 3. Identification of common-to-all model miRNAs. (A) Graphs show the overlap of up- and down-regulated miRNAs between the three models at various phases of epilepsy development. (B) The miRNAs with consistent up-regulation in all three models, common-to-all miRNAs, are further highlighted. (C) Examples of the expression data from the PPS model for the common-to-all miRNAs up-regulated in chronic epilepsy (excluding miR-146a-5p and miR-132-3p).
synaptic response to Schaffer collateral stimulation (Fig. 5 A), paired pulse facilitation (Fig. 5 B and C), and action potential properties of pyramidal neurons (Fig. 5 D and E). Taken together, these studies indicate that the antiseizure antagonists have seemingly limited and specific effects on hippocampal properties in naïve rodents.

**Combinatorial miRNA Inhibition Reduces Seizures in Experimental TLE.** Next, we investigated whether targeting the identified miRNAs could affect spontaneous recurrent seizures. For this we combined the three most effective antagonists (targeting miR-10a-5p, miR-21a-5p, and miR-142a-5p) into a single antagomir mixture (termed “combi-antimiR”). We confirmed the combi-antimiR mediated effective silencing of the three miRNA targets, comparable to the individual antagonists and with no obvious sex difference (Fig. 6 A). When preinjected with combi-antimiR, mice displayed reduced seizure severity during SE in the IAKA model, in line with the results of pretreatments targeting the three miRNAs individually (Fig. 6 B and C and **SI Appendix, Fig. S1 A and B**). Next, additional mice were subjected to IAKA and then monitored over the next 2 wk for spontaneous recurrent seizures (SRSs) (29, 31). After establishing equivalent baseline rates of SRSs (**SI Appendix, Fig. S2**), mice were randomly assigned to scramble or combi-antimiR posttreatments and SRS monitored over the next week. Combi-antimiR reduced both the occurrence and severity of seizures when administered as a posttreatment in already-epileptic mice, 2 wk after SE (Fig. 6 D and E and **SI Appendix, Fig. S2C**).

**Target and Pathway Analysis Combined with RNA-Seq and Proteomics: Reveal a Role for the TGF-β Signaling Pathway in the Antiseizure Effects of Combi-antimiR.** Finally, we sought to identify potential mechanisms underlying the antiseizure effects of the antagonists and combi-antimiR and focused on identifying convergent pathways for miR-10a-5p, miR-21a-5p, and miR-142a-5p. The putative mRNA targets of the three miRNAs were identified using both predicted (miRDip) (32) and experimentally validated [miRTarBase (33) and TarBase (34)] datasets. To reduce the risk of false positives, we applied strict miRNA–target interaction (MTI) filtering conditions based on miRDIP-assigned confidence levels and type of experimental validation (Methods). The estimated MTIs for each miRNA, along with brain expression information for each putative target, are listed in Dataset S2. We also performed in situ hybridization for miR-10a-5p, miR-21a-5p, and miR-142a-5p and this suggested neuronal as well as glial expression (**SI Appendix, Fig. S3**). While each miRNA had many unique targets, the three seizure-related miRNAs (miR-10a-5p, miR-21a-5p, and miR-142a-5p) shared 59 mRNA targets (Table S3). Nineteen of these were not targeted by miR-27a-3p or miR-431, indicating that these targets could be specific to the observed antiseizure effects (Fig. 7 A and **SI Appendix, Table S3**). Moreover, 48 mRNAs targeted by >1 of these miRNAs (of a total 525) have previously been associated with epilepsy, including GABA receptor, sodium, and potassium channel subunits (**SI Appendix, Table S4**).
We next performed Reactome pathway enrichment analysis on the predicted targets for each of the miRNAs, using targets expressed in the hippocampus, and found that 15 pathways were enriched for targets of more than one seizure-modifying miRNA (Fig. 7B). Notably, six of these pathways are associated with TGF-β signaling, including the two pathways enriched in all three miRNAs (“R-HSA-170834: Signaling by TGF-beta receptor complex” and its daughter pathway “R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3/SMAD4 heterotrimer”). On further investigation, we noted that 35/73 genes involved in these two pathways were targeted by at least one of the seizure-modifying miRNAs, including TGF-β receptor type 2 (TGF-βRII) (Fig. 7C).

To corroborate these systems-level predictions, we combined RNA-sequencing and mass spectrometry proteomic analyses on hippocampi isolated at the chronic time point (PPS model). This led to a testable prediction that derepression of TGF-β signaling may be a convergent mechanism of the targeted miRNAs. We therefore measured levels of pathway components in mice that had previously received either scramble or the combi-antimiR 24 h before SE (Fig. 6B). Western blotting revealed TGF-βRII protein levels were higher in mice treated with the combi-antimiR compared to scrambled controls (Fig. 7F and SI Appendix, Fig. S1C). To extend this, we coinjected the TGF-β pathway inhibitor galunisertib (2 mg/kg intraperitoneally [i.p.]), or vehicle control, with combi-antimiR before SE. Seizure severity was increased in combi-antimiR-treated mice coadministered galunisertib compared to vehicle (Fig. 7G), providing additional evidence for a role of TGF-β signaling in the therapeutic effects of the antagonists.

Discussion
The existence of conserved miRNA signatures in the development and maintenance of a seizure-prone state would provide important mechanistic insights and guide prioritization of miRNAs for therapeutic targeting. Here we undertook a coordinated effort, sequencing Ago2-bound miRNA to more accurately predict the regulatory potential of a given miRNA than by measuring overall miRNA levels in a sample (24), covering three different models, two species, and all stages from the initial precipitating insult to establishment of spontaneous recurrent seizures. The dataset contains robust statistics and fold change for individual miRNAs at each time point to illustrate expression variance and cross-model and cross-species comparisons. We found high concordance between the models and species in expression of known brain-enriched...
miRNAs, including miR-128-5p (35) and members of the let-7 family (36) whereas no reads were detected for nonbrain miRNAs such as miR-122-3p (liver specific) and miR-208b-3p (heart specific) (37, 38). The dataset features expected changes to neuronal activity-regulated miRNAs, including miR-132-3p (25) and miRNAs that regulate cellular responses to tissue injury, such as apoptosis-associated miR-34a-5p (39, 40). Together, the results offer important advances over previous work which focused on predetermined miRNAs (e.g., microarray based), lacked quantitative information on relative abundance, and lacked functional relevance (non-Ago2-loaded miRNAs) (21, 25, 41–45). The Ago2-sequencing (Ago2-seq) data provided in the current study are also an important companion to other databases on miRNA–epilepsy associations (46). The data complement, as well as reveal distinct profiles from Ago2-seq analysis of neural precursors (47) and should interest researchers working on disease mechanisms for which there is shared pathophysiology, such as traumatic brain injury (48).

By employing a multimodel sequencing approach, we were able to demonstrate that there are shared miRNAs dysregulated at all phases in the development of epilepsy, up to and including the period of active chronic epilepsy. Most of the miRNA changes fell within a 1.5- to 3-fold range although some, including miR-142a-5p, displayed much larger fold changes. There was no apparent species or model-specific bias, and numbers of shared miRNAs at the different stages of epilepsy development were quite similar, ranging from 6 to 18 among up-regulated miRNAs. We detected previously reported changes to miRNAs functionally linked to experimental epilepsy, including miR-22-3p (49), miR-129-5p (50), miR-134-5p (25), miR-146a-5p (27), and miR-324-5p (51). This indicates that Ago2-seq identifies robust miRNAs for targeting, a means to cross-compare between species and model, and a way to better prioritize miRNAs for functional assessment. A number of the miRNAs reported to be dysregulated in human TLE (52–54) were also differentially expressed in the chronic epilepsy state. This underscores the clinical relevance and translatability of our findings. It also invites additional predictions about human-dysregulated miRNAs which might be tested for function in animal models. The results extend evidence of a common miRNA signature in experimental epileptogenesis (23), contrasting conclusions from certain metaanalyses (22). Moreover, we report higher numbers of miRNAs and more differentially expressed miRNAs across these animal models than any previous epilepsy profiling study (21, 25, 41–45), indicating that miRNA dysregulation may impact on gene expression even more extensively than previously thought (17).

The potential for a miRNA-based therapeutic is gaining traction for disease modification in epilepsy (5, 17). LNA-based oligonucleotides as used here are particularly relevant for clinical translation as this backbone chemistry has been used in human trials of a miRNA-based therapy for hepatitis C (55). Here we show that robust antiseizure and neuroprotective effects can be achieved by targeting multiple miRNAs commonly up-regulated at the stage of chronic epilepsy. Notably, this included miRNAs...
for which there was no prior knowledge of a functional link to epilepsy. From these, we selected miRNAs which were fully conserved in humans, enhancing the translational potential of our findings. Our unbiased screen for antiseizure phenotypes identified five antagonirs that protect the brain against prolonged seizures, of which those targeting miR-10a-5p, miR-21-5p, and miR-142-5p had the most robust effects. Additionally, a combi-antimiR targeting all three miRNAs reduced spontaneous recurrent seizures when administered as a posttreatment to mice which had developed epilepsy. Taken together, this is a substantial addition to the number of miRNAs reported as potential targets for seizure control (20). It also suggests that many of the up-regulated miRNAs in the chronic epilepsy phase may be suppressing targets that would otherwise oppose hyperexcitability. While the antiseizure effects of targeting miR-10a-5p, miR-142a-5p, and the neuroprotection associated with inhibition of miR-431-5p have not previously been described, a recent study also found that targeting miR-21-5p could suppress seizures (56). Notably, our biophysical analyses of the electrophysiological properties of hippocampus from antagonist-treated rodents showed no obvious impairments. Together, these findings suggest broad safety and suitability to enter preclinical development.

The regulatory potential of miRNAs is enhanced where there is convergence upon a small number of targets or pathways (11, 12). An important effort in the present study was to combine mRNA targets of all miRNAs (experimentally validated and predicted interactions) to build superior pathways, building in a broad safety and suitability to enter preclinical development.

**Target identification and pathway enrichment analysis identified TGF-β signaling as a potential convergent mechanism of the seizure-modifying miRNAs.** (A) Number of mRNAs targeted by each miRNA. One mRNA (thyroid hormone receptor beta) is targeted by all 5 miRNAs. A total of 59 mRNAs are targeted by the 3 seizure-modifying miRNAs, 19 of which are not targeted by either miR-27a-3p or miR-431 (SI Appendix, Table S3). All targets are listed in Dataset S2. (B) Significantly enriched Reactome pathways for each of the seizure-modifying miRNAs. ** indicates pathways associated with TGF-β signaling. (C) Wiring diagram depicting miRNA targets of the 3 seizure-modifying miRNAs that are involved in the Reactome pathways: signaling by TGF-beta receptor complex and transcriptional activity of SMAD2/SMAD3/SMAD4 heterotrimer, illustrating the convergence of diverse miRNA targets at the pathway level. (D) mRNA expression levels (normalized to control) of rat hippocampi isolated at the chronic time point of the PPS model. mRNAs above the dashed lines (drawn at $-\log_{10}(q$ value $) = 1.3$ and 2.0) were considered statistically significant. Fold changes are shown on the x axis with significantly dysregulated mRNAs involved in the TGF-β signaling pathways highlighted in blue (all down-regulated). * denotes mRNAs which are targeted by miR-10a-5p, miR-21-5p, and/or miR-142-5p, as depicted in C. (E) Protein expression levels (normalized to control) of rat hippocampi isolated at the chronic time point of the PPS model. Proteins above the dashed lines (drawn at $-\log_{10}(q$ value $) = 1.3$ and 2.0) are considered statistically significant. Fold changes are shown on the x axis with proteins involved in the TGF-β signaling pathways highlighted in blue (down-regulation) and red (up-regulation). * denotes proteins which are targeted by miR-10a-5p, miR-21-5p, and/or miR-142-5p, as depicted in C. (F) Graph showing semiquantification of Western blot analysis of mouse brains taken 24 h after IAKA-induced SE shows that pretreatment with combi-antimiR derepressed TGFβ expression. Brain tissue samples were from mice in Fig. 6B, where combi-antimiR pretreatment reduced SE. (G) Coadministration of the TGF-β pathway inhibitor galunisertib occludes the antiseizure effect of combi-antimiR. (Left) Raw EEG traces show SE induced by IAKA in mice pretreated with combi-antimiR and galunisertib (blue trace) or vehicle control (red trace). (Right) TGFβ pathway inhibition with galunisertib blocks the antiseizure effects of combi-antimiR pre-treatment (EEG artifact [excluded from analysis], n = 6 mice per group, t test *P < 0.05).
of the genes targeted by two or all three of the seizure-regulating miRNAs, have previously been implicated in epilepsy.

There are some limitations and assumptions to consider in the present study. Some of the Ago2-bound miRNA pool may not be actively engaged with miRNA targets (61). Agg isoforms besides Ago2 may be important (14) and small RNA sequencing may over- or underestimate the abundance of certain miRNA species (62). We performed four functional studies to target up-regulated miRNAs using antisense oligonucleotides. This has broad safety relative to overexpressing miRNAs which could saturate the RNA interference pathway (63), but down-regulated miRNAs may also represent therapeutic targets (23). Notably, target RNA-directed miRNA degradation (TDMD) has been reported, whereby miRNAs themselves are degraded upon binding a target site of high complementarity (64, 65). However, this has rarely been seen with endogenous target RNAs and we did not find evidence that the levels of the three miRNAs of main focus were influenced by TDMD (64).

Higher levels of the three miRNAs of main focus may represent additional therapeutic targets. Finally, genetic variation in miRNA coding regions could affect expression. However, the common-to-all miRNAs here do not originate from genomic regions known to have chromosomal mutations in epilepsy (67, 68). Large-scale DNA sequencing is warranted to test the impact of adjustment of criteria for selecting miRNAs could yield additional miRNAs for functional studies. Indeed, several potentially new epilepsy-associated miRNAs not identified in multimodal or metatranscriptomics of miRNAs (21–23) showed significant regulation in two of the models here, including highly expressed miRNAs (thus likely to be functionally significant) such as miR-410-3p and miR-454-3p (down-regulated) and miR-24-3p and miR-127-3p (up-regulated). Primate or human-specific miRNAs would not have been detected by our screen and may represent additional therapeutic targets. Finally, genetic variation in miRNA coding regions could affect expression. However, the common-to-all miRNAs here do not originate from genomic regions known to have chromosomal mutations in epilepsy (67, 68). Large-scale DNA sequencing is warranted to test the impact of genetic variation on miRNA function in epilepsy covering coding genomic regions, miRNA processing genes, and miRNA target sites on miRNAs.

Conclusions

The present study generated an unique resource to explore the expression and dysregulation of miRNAs across multiple animal models of epilepsy and throughout the course of the disease. This systematic approach to discovery revealed a greater than previously anticipated, temporally specific dysregulation of miRNAs in epilepsy and showed this to be a rich source of seizure-regulatory miRNAs. The identified miRNAs are a major class of regulatory element in epilepsy with therapeutic potential for seizure control.

Methods

Animal Models of Epilepsy. All animal experiments were performed in accordance with the European Communities Council Directive (2010/63/EU). All animals were housed in on-site barrier-controlled facilities having a 12-h light-dark cycle with ad libitum access to food and water.

Procedures in rats were approved by the local regulation authority (Philips University Marburg, Germany: Regierungspraesidium Giessen, 73/2013), or according to the Animals (Scientific Procedures) Act 1986 (United Kingdom). Male Sprague-Dawley rats (250 to 325 g [Charles River] or 200 to 300 g [Harlan]) were used in all studies. Epilepsy was induced using PPS in rats, as described (69) and detailed in SI Appendix, Supplementary Methods.

Conclusions

Procedures for inducing epilepsy using the IKAKA technique in mice were approved by the Research Ethics Committee of the Royal College of Surgeons in Ireland (REC-940), under license from the Health Products Regulatory Authority (AE19127/001), Dublin, Ireland. Adult male C57BL/6 mice (20 to 25 g [Harlan]) were used, as detailed in SI Appendix, Supplementary Methods. Mice were killed at 1 h, 24 h, 48 h, 72 h, day of first spontaneous seizure (typically 3 to 5 d after SE), or at 2 wk (chronic epilepsy). At the time of killing, mice were deeply anesthetized with phenobarbital and transcardially perfused with ice-cold PBS to remove blood contaminants. Hippocampi were frozen and stored at −80 °C.

Procedures for inducing epilepsy using the PILO model in mice were approved by the University of Verona Research Ethics Committee under license from the Italian Ministry of Health (27/2014-PR). Adult male NMRI mice (Harlan) were used, as detailed in SI Appendix, Supplementary Methods. Mice were killed at 1 h, 24 h, 48 h, 72 h, day of first spontaneous seizure (typically 1 to 2 wk after SE), or at 4 wk (chronic epilepsy).

Immuno precipitation of Ago2, RNA Extraction, and Sequencing (Ago2-Seq).

Frozen hippocampi were thawed on ice. Tissue was homogenized in 200 μL of immunoprecipitation (IP) buffer (300 mM NaCl, 5 mM MgCl₂, 0.1% Nonidet P-40, 50 mM Tris HCl pH 7.5, protease and RNAses inhibitors). The homogenate was centrifuged at 16,000 × g for 15 min at 4 °C to pellet nuclei and membranes. Supernatant (considered total cell lysate) was transferred to a new tube and the cell lysate was performed to quantitate protein content of total cell lysate. The lysate was preclarified by adding 10 μL of 50% Protein A/G beads (Santa Cruz Biotechnology) to 400 μg of protein lysate, final volume was adjusted to 1 mL using IP buffer, and lysate was incubated rotating for 1 h at 4 °C, then centrifuged at 13,000 × g for 5 min at 4 °C to pellet the beads, and supernatant was transferred to a new Eppendorf tube. A total of 5 μg of AGO-2, Cell Signaling Cat. No. 2897) antibody was added preclarified cell lysate, vortexed, and incubated rotating overnight at 4 °C. A total of 20 μL of 50% A/G agarose beads was added to lysate antibody solution and incubated, rotating for 2 h at 4 °C, then centrifuged at 16,000 × g for 5 min at 4 °C, and supernatant removed. The pellet was washed twice with 500 μL IP buffer by gently resuspending pellet, centrifuging at 16,000 × g for 1 min at 4 °C, and removing supernatant. The precipitate was purified after washing, washed with 12 μL dH₂O and heated to 60 °C for 10 min. Purified RNA was stored at −80 °C until small RNA library preparation. A total of 5 μL of purified RNA was prepared using TruSeq small RNA library preparation kit (Illumina), for rat samples, using standard procedure and 12 PCR cycles and for mouse, using half the amount of primers and reagents and 15 PCR cycles. Pippin prep (Sage Science) was used to size fractionate libraries to the 140-bp to 160-bp size range. Library size and purity was validated on a Bioanalyser 2100 (Agilent) using a high-sensitivity DNA chip, and the concentration was quantified using a KAPA Library Quantification Kit. Prepared libraries were pooled as required and sequenced on a NextSeq500 (Illumina) at Exiqon.

Analysis of Small RNA Sequencing Data. FASTX-Toolkit was used to quality-filter and cutadapt was used to remove adaptor sequences. Filtered reads were mapped to a list of unwanted small RNAs and miRNAs to miRBase v21 allowing zero mismatches, but allowing for nontemplated 3′ A and T bases. Reads not mapping to miRNAs were mapped against other relevant small RNA datasets: piRNA, tRNA, snoRNA, snRNA, and Y RNA allowing one mismatch. The remaining unmapped reads were mapped to mRNA and rRNA datasets. miRNAs were normalized as reads per million miRNA mapping reads (RPM). Statistical significance was calculated by one-way ANOVA with false discovery rate (FDR) (Benjamini-Hochberg). Common-to-all miRNAs were defined as having mean basal expression above 10 RPM, while exhibiting same-directional expression change of 25% or higher in all three models at key time points, as detailed above for each model.

Systematic Antagomir Screening. Antagomir screening was performed in the IKAKA mouse model according to previously described techniques (71) and detailed in SI Appendix, Supplementary Methods. An additional subset of adult female C57BL/6 mice (Harlan, weight matched to males [20 to 25 g], coordinates for IKAKA verified by ink injection) were used in some experiments. For pretreatment studies, antagonimers or combi-antimiR (SI Appendix, Supplementary Methods) were administered 24 h before SE induction by IKAKA. A subset of mice were given the TGFβRII inhibitor galunisertib (Tocris, Cat. No. 6956, 2 mg/kg via i.p. injection; vehicle, 10% dimethyl sulfoxide in PBS). A first galunisertib injection was given at the same time as combi-antimiR, 24 h before SE, and a second injection of galunisertib alone was given 30 min before SE. Twenty-four hours after SE, mice were transcardially perfused and brains removed for histopathological analysis of hippocampal

Vene et al.
damage or molecular analysis. Seizure-induced neuronal damage was anal- 
alyzed on 12-μm coronal sections at the level of medial hippocampus (AP = −1.70 mm) using Fluoro-Jade B (Millipore Ireland B.V.) as de- 
scribed (70). For posttreatment study, combi-antimir was given 14 d after 
induction of SE by IAKA and mice were perfused 21 d after SE.

RNA Extraction and RT-qPCR to Assess Antagonist-Mediated miRNA Knockdown. 
Hippocampi were homogenized in 750 µL of TRIzol and centrifuged at 12,000 × g for 10 min at 4 °C. Phase separation was performed by adding 200 µL of chloroform to each sample and vigorously mixing for 5 s before incubating at RT. Samples were centrifuged at 15,600 × g for 15 min at 4 °C. The upper 
phase was removed and 450 µL of isopropanol was added and samples were 
stored at −20 °C overnight. Samples were centrifuged at maximum speed 
for 30 min at 4 °C. A total of 750 µL of 75% cold ethanol was used to wash the 
pellet. Samples were centrifuged at 13,300 × g for 5 min and the ethanol 
was removed. This step was repeated twice. The pellets were left to dry for 1 h and 
resuspended in 25 µL of RNase free H2O. Samples were incubated for 10 min 
at 60 °C with 60 °C of agitation. Samples were stored at −80 °C. A total of 500 ng 
was reverse transcribed using stem-loop Multiplex primer pools (Applied Bio-
systems). We used reverse-transcribease-specific primers for the hsa-miR-10a 
(Applied Biosystems miRNA assay ID 000387), hsa-miR-21a (Applied Biosystems 
miRNA assay ID 000397), and hsa-miR-142a (Applied Biosystems miRNA assay ID 
002248) and real-time quantitative PCR was carried out on a 7900HT Fast Real-
time System (Applied Biosystems) using TaqMan miRNA assays (Applied Bio-
systems miRNA assay ID 000387), hsa-miR-21a (Applied Biosystems 
miRNA assay ID 000397), and hsa-miR-142a (Applied Biosystems miRNA assay ID 
002248) and real-time quantitative PCR was carried out on a 7900HT Fast Real-
time System (Applied Biosystems) using TaqMan miRNA assays (Applied Bio-
systems). U19 (Applied Biosystems miRNA assay ID 001003) was used for 
normalization. A relative fold change in expression of the target gene transcript 
was assessed using the ΔΔCt method.

In Vitro Assay of Effects of Anti-mir-10a-5p, Anti-mir-21a-5p, and Anti-mir-142a-5p. 
Stereotactic injection for each miRNA knockdown was performed on adult male 
Sprague-Dawley rats (weight range 270 to 380 g) as described previously (30) 
and detailed in SI Appendix, Supplementary Methods. Ex vivo brain slices were 
prepared between 2 and 4 d after surgery, to coincide with the maximal miRNA 
silencing effect (30). All slice electrophysiology was performed using a mem-
brane chamber (30) perfused with oxygenated recording artificial cerebrospinal 
fluid (ACSF), heated to 34 °C, at a rate of 16 ml/min. Electrophysiological data 
were acquired using a Multichannel 7000 Data Acquisition System (Motorized 
Devices), digitized at 10 kHz with a Power1401 (Cambridge Electronic Design), 
and recorded using Signal software (Cambridge Electronic Design). For extracellular 
recordings, we stimulated the Schaffer Collateral pathway with a concentric 
binocular stimulating electrode (FHC, CBARC57) and recorded the response in CA1 
stratum radiatum using a thin-walled borosilicate glass microelectrode (−5 MΩ) 
filled with recording ACSF (in mM: 125 NaCl, 10 glucose, 26 NaHCO3, 1.25 
KCl, 2 CaCl2, 1 MgCl2). Patch clamp recordings used −5-MΩ glass 
microelectrodes filled with intracellular solution (in mM: 135 K-glutamate, 4 KCl, 
10 Hepes, 4 Mg-ATP, 0.3 Na-GTP, 10 Na2-phosphocreatine, pH 7.3; 290 mMOSm). 
After at least 5 min, neurons were injected with a series of hyperpolarizing and 
depolarizing current steps (100-ms current injections with 1 s between 
steps; −100 to +400 pA in 25-pA increments). The first action potential elicited by 
a depolarizing step was selected for analysis. All recordings were made with 
bridge balance compensated, access resistance <2 MΩ, and rejected if action 
potentials did not overshoot 0 mV.

Bioinformatics: mRNA Target Identification, miRNA Target Interaction (MTI) 
Prioritization, and Pathway Enrichment Analysis. Predicted MTIs were down-
loaded from miRDiP V4.1, a database that integrates 30 prediction algorithms 
and calculates an MTI confidence score based on statistical inference (32). 
Experimentally validated MTIs were downloaded from miTarBase V7 (33) 
and calculated using an in-house database 
collating information from CARPEdB [http://carpedb.ua.edu], epiGAD (77), 
and curated epilepsy genes from the Comparative Toxicogenomics Database 
[ctdb.nci.nih.gov] (78). 

Pathway analysis was performed on Reactome pathways containing 10 to 
500 genes by applying the cumulative hypergeometric distribution for Pvalue 
comparison (80). Pathways with corrected P values of <0.05 (Benjamini– 
Hochberg) were considered significantly enriched.

RNA Sequencing (miRNA). RNA was resequenced using the Ribosomal Magnetic 
Kit (human/mouse/rat; Illumina). Sequencing libraries were generated 
using the ScriptSeq v2 kit (Illumina), quality controlled on the 2100 
Bioanalyzer (Agilent). Sequencing was done on an Illumina HiSeq sequencer.

Sequencing data were quality controlled and adaptor trimmed using Trim 
Galore. Filtered data were mapped to the rat genome Rn6 using TopHat2. 
Cufflinks was used to assemble transcripts from the mapped reads guided by gene 
annotation from Ensembl Release 87. Cuffmerge, cuffquant, and cuffdiff (part 
of the Cufflinks software package) were used to quantify transcript abundance 
each sample and to perform differential expression analysis of genes and gene 
isoforms. P values were corrected for multiple testing using Benjamini–Hochberg 
correction.

Proteomic Analysis. Hippocampi for proteomic analysis were taken from rats 
at the chronic time point of the PPS model and processed as detailed in SI Ap-
pendix, Supplementary Methods. Differential expression was evaluated using 
a combined limma and rank product test to obtain q values controlled on the 2100 
Bioanalyzer (Agilent). Sequencing was done on an Illumina HiSeq sequencer.

Available of Data and Materials. The sequencing data have been deposited to 
the Gene Expression Omnibus (GEO) under accession no. GSE137473 (81). 
The proteomics data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the dataset identifier PV001988 (82). Custom analysis codes are available at https://github.com/ 
g-morris/Ago2Seq. All data generated or analyzed during this study are in-
cluded in this published article (and its SI Appendix files). For questions on 
the MTI analysis, contact jprehn@rcsi.ie.

ACKNOWLEDGMENTS. We thank Lisa Anne Byrne for support with ethics 
and Anne Farch Nielsen, for careful editing and suggestions on the manu-
script. We thank Nora Kalabrez and Christian Siebert for help with EEG 
evaluation in the PPS model. This publication has emanated from research 
conducted with the financial support of the European Union’s “Seventh 
Framework Programme” (FP7) under Grant Agreement 602130 (EpiMiRNA). 
Additionally, this publication has emanated from research supported in part 
by a research grant from Science Foundation Ireland (SFI) under Grant 16/RC/ 
3948 and cofunded under the European Regional Development Fund and by 
Funders of the industry partner. Additional support from SFI was through 
grants SFI/13/IA/1891 and 12/COEN/18. G.M. and J.P.H. are supported by 
the MTI analysis, contact jprehn@rcsi.ie.

1. S. U. Schuel, H. O. Lüders, Intractable epilepsy: Management and therapeutic al-
ternatives. Lancet Neurol. 7, 514–524 (2008).
2. P. Kwan, S. C. Schachter, M. J. Brodie, Drug-resistant epilepsy. N. Engl. J. Med. 365, 
919–926 (2011).
3. I. Blumcke et al; EEEB Consortium, Histopathological findings in brain tissue obtained 
during epilepsy surgery. N. Engl. J. Med. 377, 1648–1656 (2017).
4. A. Piskunova, K. Buettner, I. Blumcke, Mechanisms of epileptogenesis and potential treatment 
targets. Lancet Neurol. 10, 173–186 (2011).
5. O. Devinsky et al., Epilepsy. Nat. Rev. Dis. Primers 4, 18024 (2018).
6. J. A. Gorter et al., Potential new antiepileptogenic targets indicated by microarray 
analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 26, 11083–11110 (2006).
7. S. McClelland et al., The transcription factor NR5F contributes to epileptogenesis by 
selective repression of a subset of target genes. eLife 3, e01267 (2014).
8. M. R. Johnson et al., Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant 
gene network in human epileptic hippocampus. Nat. Commun. 6, 6031 (2015).
9. P. K. Srivastava et al., A systems-level framework for drug discovery identifies Cflr as 
an anti-epileptic drug target. Nat. Commun. 9, 3561 (2018).
10. K. S. Kosik, The neuronal microRNA system. Nat. Rev. Neurosci. 7, 911–920 (2006).
